Clinical trial · Observational
Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization
Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization and Its Impact on Overall Survival
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The application of transarterial chemoembolisation (TACE) with drug-eluting beads in patients with hepatocellular carcinoma and its response to the treatment will be observed. The registry has the following objectives: To assess the response to the treatment by standard methods and volumetric analysis as well as trying to determine any predictive response factors To determinate interobserver variability of the methods.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Hepatocellular Carcinoma by BCLC Stage | Hepatocellular Carcinoma by BCLC Stage | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Transarterial Chemoembolization | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Predictive factors for overall survival and progression-free survival
- timeFrame
- 4 years 11 months
- description
- RECIST, mRECIST, volumetric analysis
- measure
- Interobserver variability of the methods used for assessing tumor response to the treatment
- timeFrame
- 4 years 11 months
- description
- RECIST, mRECIST, volumetric analysis
Secondary outcomes (5)
- measure
- Time from observation until death due to any cause (or censoring)
- timeFrame
- 4 years 11 months
- description
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosis of HCC by a radiologist according to the European Association for the Study of the Liver (EASL) criteria or confirmed histologically * at least one TACE undergone at the University Hospital Brno * initial/ closing CT (Brillance 64, Philips, Netherlands; contrast enhancement 125 mL Iomeron 400, Bracco, Germany) or MRI study (Achieva, Philips, Netherlands, SENSE XL Torso coil 16 1.5T; contrast enhancement 15 mL Primovist, Bayer, Germany) * follow-up on or before December 31, 2019. Exclusion Criteria: * when the inclusion criteria are not met.
References
Publications (0)
Data not yet available